Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Subcutaneous Rybrevant (amivantamab co-formulated with rHuPH20) with lazertinib, first-line EGFR-mutated NSCLC; monotherapy for exon 20 insertion NSCLC after platinum; Halozyme release dated 7 April 2025
Product first approved 2025ir.halozyme.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Non-Small Cell Lung Cancer

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj): this drugApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026ApprovalFDA grants accelerated approval to Rybrevant Faspro in head and neck cancer
US, FDA · Johnson & Johnson · Source ↗
30 July 2026Priority reviewFDA grants Priority Review to RYBREVANT FASPRO sBLA in head and neck cancer
US, FDA · Source ↗
17 February 2026ApprovalFDA approves monthly dosing schedule for RYBREVANT FASPRO
US, FDA · Source ↗